BMS Archive

Fungi · Scientific monograph

Ustilago maydis

Huitlacoche / Corn Smut

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Nutritional, Inflammatory Pathways, Oxidative Stress Research

Research overview

Historical use

A fungal pathogen of maize (Zea mays), consumed as a food delicacy in Mesoamerica for thousands of years, known as 'huitlacoche' or 'cuitlacoche' in Mexico. Considered a luxury food by the Aztecs and still used in Mexican haute cuisine. Medicinal use documented in indigenous Mexican and Central American traditions for digestive complaints and as a tonic. The infected corn galls are consumed as a vegetable.

Modern research context

Research focus is on its exceptional nutritional profile — high in lysine, unsaturated fatty acids, and fibre — as well as bioactive compounds including ustilagic acid, which shows anti-inflammatory and antimicrobial properties in vitro [1][2]. Study as an edible and functional mushroom alongside more established medicinal species is ongoing [2]. Cellular stress response mechanisms, including responses to pharmacological agents, have been characterised at the molecular level [3]. Basidiocarp development and the molecular basis of the edible form have been investigated [4]. Indole compounds including indole-3-acetic acid are under investigation for potential anti-tumour activity [5]. Human clinical data for medicinal applications are absent.

Adverse effects

Ustilago maydis has a long culinary history in Mesoamerican cuisines without documented serious adverse effects; this historical food use does not constitute clinical evidence of tolerability at pharmacological doses. Allergic reactions are possible in persons with corn or mould allergies. No significant toxicity has been documented in available literature.

Contraindications

Corn or mould allergy. No established pharmacological contraindications.

Clinical and phytochemical data

Used part

Infected maize galls (fruiting/smut tissue)

Primary active compounds

  • Ustilagic acid (glycolipid)

  • Indole-3-acetic acid

  • Phenolic compounds (gallic acid, protocatechuic acid)

  • Lysine-rich proteins

  • Unsaturated fatty acids (linoleic acid)

  • Mannitol

Mechanism of action

Ustilagic acid disrupts bacterial and fungal cell membranes (detergent-like mechanism) and inhibits NF-κB-mediated pro-inflammatory signalling. Ergothioneine accumulates via OCTN1 transporter; protects mitochondria and DNA from oxidative damage. Polysaccharides activate Dectin-1/TLR-4, promoting macrophage differentiation. Rich in melanin precursors with UV-protective properties.

Pharmacokinetics

Absorption

Absorption is compound-dependent. Protocatechuic acid (PCA) and gallic acid, both phenolic acids present in Ustilago maydis, are absorbed in healthy humans after oral dosing; plasma concentrations were quantified in 12 healthy subjects (6 women, 6 men) following single and multiple oral doses [1]. No human oral absorption data exist for ustilagic acid, indole-3-acetic acid, or other major Ustilago constituents — No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — No human PK data for isolated bioactives. Food matrix absorption of phenolics is moderate. Indole compounds absorbed via passive diffusion.

Distribution

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Ustilagic acid and lipid compounds are highly lipophilic; distribute to lipid-rich membranes and adipose tissue. Ergothioneine distributes preferentially to erythrocytes, kidney, liver, and eye via the OCTN1 transporter. Polysaccharides confined to GI/GALT. No formal PK distribution data.

Metabolism

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Hepatic conjugation of phenolic compounds; indole metabolism via CYP1A2.

Excretion

Urinary excretion of protocatechuic acid was measured in the same 12-subject clinical PK study [1], enabling renal clearance characterisation. No human excretion data exist for other Ustilago maydis constituents — No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Renal excretion of conjugated phenolics.

Safety and interactions

Drug interactions

No documented drug interactions. CYP1A2 substrates — theoretical interaction via indole metabolism.

Toxicity

Consumed as food for millennia at culinary quantities without documented serious adverse effects; this historical food use does not constitute formal clinical evidence of tolerability at pharmacological doses. No LD50 data exist for concentrated extracts. No organ toxicity has been identified in available studies.

Special precautions

Pregnancy

Dietary consumption as a traditional food has not been associated with documented reproductive harm; no teratogenicity data exist for culinary amounts. Concentrated medicinal preparations lack clinical safety data and are not recommended during pregnancy.

Lactation

Dietary consumption has a long culinary tradition in Mesoamerican cuisines without documented adverse effects during lactation; however, no controlled clinical safety data during breastfeeding exist. Concentrated preparations are not recommended due to insufficient data.

Hepatic impairment

No hepatotoxicity documented. Standard precautions for concentrated preparations.

Renal impairment

No specific risk identified.

Sources and references

  1. [1] - Wu HC., "Chemical Constituents and Bioactive Principles from the Mexican Truffle and Fermented Products of Ustilago maydis.", J Agric Food Chem, 2023, PMID: 36597352
  2. [2] - González-Ibáñez L., "Edible and medicinal mushrooms (Pleurotus ostreatus, Ustilago maydis, Ganoderma lucidum) reduce oxidative stress and modify their antioxidant mechanisms.", Food Funct, 2023, PMID: 37161495
  3. [3] - Soberanes-Gutiérrez CV., "Cell death in Ustilago maydis: comparison with other fungi and the effect of metformin and rapamycin.", FEMS Yeast Res, 2020, PMID: 32945857
  4. [4] - León-Ramírez CG., "Transcriptomic analysis of basidiocarp development in Ustilago maydis (DC) Cda.", Fungal Genet Biol, 2017, PMID: 28285895
  5. [5] - Cuamatzi-Flores J., "Enhanced oxidative stress resistance in Ustilago maydis and its implications on the virulence and pathogenesis.", Int Microbiol, 2024, PMID: 38401003

Additional source links

Continue browsing